PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.89%
Negative net income growth while CRWD stands at 1598.60%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
51.98%
D&A growth well above CRWD's 10.77%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-199.65%
Negative yoy deferred tax while CRWD stands at 61.96%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
12.80%
Less SBC growth vs. CRWD's 25.92%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-525.97%
Both reduce yoy usage, with CRWD at -129.76%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-126.74%
Both yoy AR lines negative, with CRWD at -147.47%. Martin Whitman would suspect an overall sector lean approach or softer demand.
391.88%
Inventory growth of 391.88% while CRWD is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
-307.66%
Negative yoy AP while CRWD is 183.96%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
32.42%
Lower 'other working capital' growth vs. CRWD's 147.21%. David Dodd would see fewer unexpected short-term demands on cash.
1314.29%
Well above CRWD's 4.06%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-38.35%
Both yoy CFO lines are negative, with CRWD at -18.65%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
1.84%
Lower CapEx growth vs. CRWD's 23.48%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
-5383.05%
Both yoy lines negative, with CRWD at -996.62%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
49.67%
Purchases well above CRWD's 79.17%. Michael Burry would see major cash outflow into securities vs. competitor’s approach, risking near-term FCF.
-72.68%
Both yoy lines are negative, with CRWD at -33.33%. Martin Whitman suspects an environment prompting fewer sales or fewer maturities within the niche.
237.17%
Less 'other investing' outflow yoy vs. CRWD's 996.62%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
-14399.20%
Both yoy lines negative, with CRWD at -36.76%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-94.40%
We cut debt repayment yoy while CRWD is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-61.90%
Negative yoy issuance while CRWD is 1669.37%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
17.20%
Buyback growth of 17.20% while CRWD is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.